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The studies reported in this investigation involved
the characterization of the nucleoside transport system at
the subcellular level in cardiac tissue, in an attempt to
augment the knowledge of adenosine's role in
cardiovascular function. A protocol was developed that
produced a substantially pure mitocondrial fraction.
Kinetic and pharmacologic studies showed that [^H]NBMPR
binds to and labels populations of binding sites that
appear to recognize adenosine as a probable substrate.
Results from this data provide analytical probes for
further binding site studies. Therefore, additional
investigation is warranted in order to fully understand
the interactions of adenosine and assess the mechanism by
which the nucleoside produces its physiologic effects in
the heart.
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Adenosine, a naturally occurring purine nucleoside
metabolite, exerts dramatic physiological effects on the
cardiovascular system. These effects have been reported
to modulate processes such as vascular blood flow (Berne,
1980); platelet aggregation (Dawicki et al., 1985; Stiles,
1990); myocardial contractility (Belardinelli et al.,
1983; 1989); neuromodulation, lymphocyte differentiation
and lipolysis (Stiles, 1990).
It has been recognized that the nucleoside transport
system (NTS), located in the plasma membrane, is a
principal regulatory mechanism for the cardiovascular
effects of adenosine. It is this transport mechanism that
mediates the rapid uptake of adenosine into cells, thereby
shortening its biological half-life and terminating the
actions of the nucleoside (Plagemann and Wohlueter, 1980;
Paterson et al., 1981). This rapid transport of adenosine
across the plasma membranes occurs prior to its enzymatic
inactivation. Thus, only trace amounts of the nucleoside




The short-lived actions of adenosine, however, can be
enhanced or potentiated by inhibiting its transport into
cells (Stafford, 1966; Kolassa et al., 1971; Belardinelli
et al., 1982). Consequently, a variety of compounds have
been found to inhibit nucleoside transport which include
agents such as the N®-substituted 6-thiopurine nucleosides
nitrobenzylthioinosine (NBMPR) and
nitrobenzylthioguanosine (NBTGR) and other inhibitors such
as dipyridamole (DPR), hexobendine, and dilazep (Olsson et
al., 1972; Kolassa and Pfleger, 1975; Kolassa et al.,
1978; Paterson et al., 1980; Lee and Jarvis, 1986).
Although information has been provided to explain how
the actions of adenosine are potentiated, its role in
cardiovascular function and the mechanism(s) of its
actions to date have not been clearly defined. It is
believed, however, that various physiological functions of
adenosine in heart and other tissues are mediated by
interactions with specific extracellular membrane
receptors that are coupled to membrane-bound adenylate
cyclase. These receptors are capable of inhibiting or
stimulating the enzyme. Moreover, studies of adenosine
antagonists such as aminophylline, various adenosine
analogs and xanthine derivatives support evidence of these
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cell surface receptors (Alfonso, 1970 and Olsson et al.,
1977), which are located in coronary smooth muscle and
atrial ventricular muscle (Dutta and Mustafa, 1979; 1987;
Goodman and Synder, 1982). Based on pharmacological and
biochemical studies, these receptors have been classified
as A-j and A2 receptor subtypes according to their ability,
in certain tissues, to inhibit (A^) or stimulate (A2)
adenylate cyclase (Olsson et al., 1977; Schrader et al.,
1977; Burnstock, 1980), and on the rank order of potencies
with which adenosine agonists compete with a given
radioligand for binding to the receptors. Additionally,
a "P" site, a putative intracellular site located on the
catalytic unit of adenylate cyclase, has been reported to
directly inhibit its activity via ribose-modified
adenosine analogs. The physiological significance of this
site is unknown, although it has been shown to be
pharmacologically distinct from the adenosine receptors
(Haslam et al., 1978). A number of adenosine analogs
exist, however, that contain a desired selectivity for the
different receptor subtypes, depending on the
pharmacological effects of interest. Furthermore,
adenosine receptors modulate adenylate cyclase activity
via G proteins, Gg and Gj^ for the A2 and A^ adenosine
receptors, respectively. A^ receptors have been recently
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reported to be coupled to additional effector systems
including guanylate cyclase, potassium channels, and
phosphoinositol metabolism (Karachi et al., 1986; Kurtz,
1987; Ramkumar et al., 1988).
Presently, a limited amount of information is
available on the cardiovascular nucleoside transport
system. Although the importance of the NTS to
cardiovascular effects of adenosine has been recognized,
its relevance to the adenosine-mediated regulation of
cardiovascular function has not been sufficiently
investigated. Consequently, an understanding of the
mechanism(s) involved in adenosine's modulation of blood
flow and in cardiovascular function still warrants
attention. Therefore, the major objective of this
investigation is to evaluate the role of nucleoside
transport inhibition as a means to delineate the role of
adenosine in cardiovascular function.
Moreover, it is important to consider the functional
significance of the nucleoside transporters in the actions
of adenosine. Since it is not known if the distribution
of nucleoside transporters and adenosine receptors is
similar, it is hoped that studies in subcellular fractions
in the heart will provide information that will assist in
answering this question.
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The author has chosen to examine the role of
nucleoside transport inhibition in cardiovascular function
via the characterization of site-specific binding of
[^HjNBMPR to adenosine transport sites in pure guinea pig
cardiac mitochondrial fractions. Mitochondria comprise
approximately 25-35% of tissue protein in the heart (Page
and McCallister, 1973; Palmer et al., 1977; Sordahl and
Stewart, 1980). They are the major source of ATP in the
normally functioning heart (Neely and Morgan, 1974) and
contain most of the enzymes involved in energy
transduction. More than 90% of cellular AMP, a direct
precursor for adenosine, is located in the mitochondrial
compartments (Bunger et al., 1983).
Coronary blood flow has been proposed to be coupled
to tissue oxygen demand and regulated by the release of
adenosine. Since the mitochondria are the sites of oxygen
utilization and have been reported to produce adenosine
(Bukoski et al., 1983), it seems feasible that these
organelles may contain nucleoside transporters or perhaps
employ a mechanism by which adenosine may be transported.
It is anticipated through this investigation that it will
be determined if there is a subcellular basis for the
nucleoside transport mechanism in myocardial function and
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If mitochondria play a role in nucleoside transport in the
heart.
In order to address the current issues concerning the
cardiovascular nucleoside transport system, the following
specific research objectives were designated: (1) the
isolation and purification of mitochondrial fractions from
the guinea pig heart; (2) the identification and
assessment of purity of the mitochondrial fractions via
enzyme assays: Na*-K*-ATPase activity, Ouabain-sensitive-
Na'^-K'*’-ATPase activity, Ca‘*^*-Stimulated-Mg*'*^-ATPase
activity, and Cytochrome C Oxidase activity and also by
electron microscopy; (3) the localization and
characterization of nucleoside transporters of isolated
myocardial cardiac mitochondria, by radioligand binding in
terms of association and dissociation kinetics; (4) the
determination of the dose-response relationship of
nucleoside transport inhibitors and adenosine analogs for
the binding site; and (5) the comparison of [^H]NBMPR
binding parameters to those in crude guinea pig
ventricular membranes.
It should be noted that site-specific binding studies
using radioligand probes at the subcellular level require
a pure fraction. In the past, it has been difficult to
isolate a mitochondrial fraction from the heart with
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sufficient purity, due to the makeup of cardiac tissue.
As a result, the isolation of a relatively pure
mitochondrial fraction will be of major priority in this
investigation.
Finally, it is anticipated that data provided by this
study will enhance our understanding of adenosine's




Adenosine and Nucleoside Transport: A General Overview
The nucleoside transport system is a facilitated
diffusion carrier system that accepts a variety of purine
and pyrimidine nucleosides and plays an integral role in
regulating the nucleoside adenosine. Nucleoside transport
refers to the mediated bidirectional passage of nucleoside
molecules across the plasma membrane of cells via
nucleoside-specific transporter elements (Paterson et
al., 1981). Subsequently, a rapid nucleoside uptake
process results and involves the cellular accumulation of
a nucleoside permeant and its metabolic products.
Nucleoside transport occurs via a number of
facilitated diffusion processes, some of which can be
blocked by compounds that bind to nucleoside transport
sites and inhibit transport. Using the nucleoside
adenosine and vasodilator agents such as dipyridamole and
dilazep (Mustafa, 1979), and the benzodiazepine compound
diazepam (Clanachan and Marshall, 1980), early studies
were done to investigate the inhibition of nucleoside
8
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transport. Later investigations studying adenosine
accumulation in guinea pig cardiac muscle (Baker and
Clanachan, 1982), focused attention on the difficulty of
actually measuring adenosine transport rates because of
the rapid rate of adenosine uptake. Accordingly, drug-
induced inhibition of adenosine accumulation could not be
used as an indicator of adenosine transport inhibition.
To circumvent the problem of measuring the rate of
transport, the binding of [^HjNBMPR to guinea pig cardiac
membranes was described and suggested as an alternate
method of investigating the NTS in the heart (Williams and
Clanachan, 1982).
Although a large variety of compounds have been found
to inhibit nucleoside transport, dipyridamole and the
purine analogs NBMPR and NBTGR have been the most useful
probes of the nucleoside transport mechanism (Paterson et
al., 1981). NBMPR, which is among the most potent and
best studied of the group of nucleoside transport
inhibitors, had been tritium labeled and was used as a
radioligand to study the nucleoside transport system in
the guinea pig heart (Williams and Clanachan, 1982).
NBMPR was reported to bind saturably and reversibly to a
single class of high affinity sites in these membranes
which exhibited binding characteristics similar to those
10
observed for human erythrocytes (Hammond et al., 1981).
Other investigators used the triated NBMPR to study
nucleoside transport in various systems. The radioligand
was shown to bind to an apparently homogeneous population
of binding sites in rat and guinea pig brain preparations
in a rapid and specific manner (Marangos et al., 1982).
Similarly, reversible and high affinity NBMPR binding to
specific sites on nucleoside transport elements of HeLa
cells, presumably on the plasma membrane, was also
reported (Hammond and Clanachan, 1985).
Unlike NBMPR, dipyridamole has been used extensively
as a vasodilator and is well characterized in animals for
its ability to potentiate the actions of adenosine (Morgan
and Marangos, 1987). Its inhibition characteristics of
adenosine accumulation were studied and compared to those
of NBMPR in rat and guinea pig synaptosomes. Data from
these studies revealed inhibition of adenosine
accumulation to be distinctly biphasic and monophasic by
NBMPR and dipyridamole, respectively, in all preparations
studied. Further investigations revealed that [^H]-
dipyridamole labeled substantially more binding sites per
unit protein than [^H]NBMPR in guinea pig cortical
membranes as compared to rat tissue (Marangos et al.,
1985; Deckert, 1985). These observations support the
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hypothesis that both compounds can bind to functionally
relevant sites and that different populations of
nucleoside transporters exist in mammalian brain.
Nucleoside transport systems differ among species and in
tissues in a number of criteria (Parkinson and Clanachan,
1989). Sensitivity to inhibitors of nucleoside transport,
primarily NBMPR and dipyridamole has been the basis by
which facilitated diffusion systems have usually been
subclassified. Hopkins and Goldie (1971) showed that
dipyridamole does not potentiate adenosine effects in rat
tissue. Additional studies revealed that dipyridamole,
lidoflazine and hexobendine have significantly lower
affinity for nucleoside transport systems in rat tissue
than in other species, particularly guinea pig. Moreover,
Williams and colleages (1984), compared the
characteristics of the site-specific binding of [^HjNBMPR
to cardiac membranes of several mammalian species. The
affinity of the radioligand for these sites and the
maximal binding capacity of cardiac membranes for
[^H]NBMPR were both species dependent. Other
investigations showed dipyridamole and dilazep to inhibit
NBMPR binding in some Central Nervous System (CNS)
preparations in a biphasic manner (Hammond and Clanachan,
1984; 1985). These membrane preparations possessed
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apparent uniform populations of NBMPR binding sites.
Recently, regional subtypes of facilitated diffusion
nucleoside transport systems have been discovered and
identified. Systems of high and low sensitivity of NBMPR
were identified in several lines of cultured cells
(Paterson et al., 1987) and to dipyridamole in guinea pig
and rat myocytes, respectively. More recently. Shank and
Baldy (1990) reported differences in adenosine transport
systems of the rat and guinea pig. NBMPR-sensitive
systems were pharmacologically different in the two
species in that certain compounds (i.e., dipyridamole and
mioflazine) proved to be more potent inhibitors in the
guinea pig.
Investigations of cardiovascular adenosine transport
systems are steadily being conducted. [^H]NBMPR binding
studies were done in smooth muscle and endothelial cells
(Williams et al., 1990). The presence of nucleoside
transport elements in cultured primate vascular smooth
muscle, bovine aortic endothelial, and human umbilical
vein endothelial cells were reported with multiple
[^H]NBMPR binding sites being detected in human umbilical
vein endothelium. Based upon their findings, the
investigators concluded that the actions of adenosine in
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these tissues are enhanced by dipyridamole and other
agents and that these effects can be attributed, in part,
to interaction with the nucleoside transporter elements in
vascular smooth muscle and endothelium.
Physiological Effects of Adenosine
The profound physiological effects of adenosine was
first recognized by Drury and Szent-Gyorgyi approximately
60 years ago when it was demonstrated that the nucleoside
linked cardiac metabolism to coronary and vascular smooth
muscle tone. Adenosine's effects are not limited,
however, to the cardiovascular system. Almost all organs
of the body are regulated to some extent by its release
(Table 1). Consequently, the diverse roles of adenosine
and its physiological properties, along with the potential
therapeutic value of adenosine transport inhibitors,
stimulated the current interest in adenosine transport
systems.
The most prominent physiologic role of adenosine has
been in cardiovascular function where its effects cause
vasodilation, hypotension, and cardiac depression (Kusachi
et al., 1983; Leung et al., 1983).
From a pathophysiological perspective, adenosine has
recently been reported to be released as a pharmacologic
14
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agent for the treatment of cardiac dysrhythmias (Stiles,
1990) in addition to functioning as a hypotensive agent in
hypertension.
Additionally, the antilipolytic, antithrombotic, and
antispasmodic actions of adenosine result in varied
responses that are linked to adenylate cyclase activity in
different cell types. The inhibition of adenylate cyclase
in adipocytes activates the antilipolytic actions; the
activation of adenylate cyclase in platelets by adenosine
results in the inhibition of platelet aggregation; and the
activation of muscle adenylate cyclase produces depressant
effects that are linked to the antispasmodic and
vasodilatory actions of adenosine. Secondly, adensoine
has been demonstrated to function as an endogenous
neuromodulator in the mammalian CNS (Dunwiddle, 1985) and
to exert inhibitory effects on neurotransmission and
spontaneous activity of the CNS neurons (Daly, 1982). The
mechanism for the inhibitory actions was thought to
involve calcium ions and the presynaptic inhibition of
adenylate cyclase. The inhibitory effects of adenosine on
cholinergic and noradrenergic transmitter release were
demonstrated to be reversed by calcium ions. As a result,
adenosine and its analogs came to be referred to as
calcium antagonists. A third effect of adenosine is its
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stimulatory action in adrenal cells that lead to
steroidogenesis, again as a result of adenylate cyclase
activity. More recently, studies of adenosine's
vasodilatory effects were extended to endothelial tissue.
It was observed that adenosine induced stimulation of
adenylate cyclase activity in endothelial cells via its
direct actions on the enzymes's catalytic P site subunit
(Legrand et al., 1990). Further studies revealed that
adenosine also stimulated the proliferation and migration
of bovine aortic or coronary microvascular endothelial
cells {in vitro) in response to hypoxia (Meininger et al.,
1988; 1990).
Finally, the actions of adenosine can also produce
vasconstrictory effects. In the lungs, the actions of
adenosine involves bronchoconstriction. It has been
concluded that adenosine exerts its actions on airways by
modulating mast cell degranulation (Cushley and Holgate,
1985) and by inducing immediate bronchoconstriction in
asthmatic airways (Fredholm, 1980; Ukenar et al., 1985).
Further studies by Holgate and colleages to determine the
nature of bronchoconstriction produced findings that
suggested that adenosine acts at a cell surface receptor,
probably of the A2 type, to elicit bronchoconstriction
responses. Another organ in which the effects of
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adenosine result in vasoconstriction instead of
vasodilation is the kidney. Unlike the lungs, however,
the mechanisms involved in these vasoconstrictor actions
are still poorly understood and require more
investigation.
Adenosine Formation eind Release
In contrast to the progress made in assessing the
mechanisms of adenosine's actions, considerable
controversy still exist concerning the sites of adenosine
production and the mechanism of its release in the heart.
Similarly, the significance of the metabolic pathways
involved in the formation and inactivation of adenosine is
still unresolved.
Three pathways (Fig. 1) have been proposed as
potential sources of adenosine in the heart: (1) ecto-5'-
nucleotidase (Frick and Lowenstein, 1976; Lowenstein et
al., 1983); (2) cytosolic 5'-nucleotidase (Gibson and
Drummond, 1972; Lowenstein et al., 1983; Itoh and Oka,
1985; Meghji et al., 1988) and (3) S-adenosylhomocysteine
(Schrader et al., 1981). ATP utilization leads to
increased cytosolic levels of 5'-nucleotidase. The
cytosolic form of 5'-nucleotidase is currently thought to
be more important in producing intracellular adenosine
Figure 1. Schematic Diagram Showing the Pathways of
Adenosine Formation, Production and Its
Fate in the Heart (Adapted from Feigh,
1983).
A) The ectoenzyme, 5-nucleotidase ,
dephosphorylates 5'-AMP to adenosine
B) Cytosolic 5'-nucleotidase produces
an Intracellular source of adenosine
C) S-adenylhomocysteine (SAH) produces
















than the membrane-bound ecto-enzyme (Van den Berghe et
al./ 1977; Itoh, 1981; Worku and Newby, 1983; Newby et
al., 1987), even though its regulation remains to be fully
explored. Alternatively, S-adenosylhomocysteine is
hydrolyzed to adenosine. Adenosine is thought to leave
the cardiac myocyte via carrier-mediated diffusion and
enters the interstitial space where it is transported into
a variety of cell types. Interactions on vascular smooth
muscle is thought to increase cAMP levels and subsequent
relaxation. Adenosine that is transported into cells is
either deaminated or phosphorylated.
Regulation of Adenosine Receptors (Signal Trauisduction
Mechanism)
The effects of drugs and hormones can be modulated by
cells via cell surface receptors. Chronic exposure of
these receptors to agonists can result in an uncoupling of
the receptor from the effector system. This uncoupling
may lead to the densensitization of the inhibitory effects
of agonists or to an enhanced response to stimulatory
agents (Rail and Wutherland, 1990; Williams, 1990).
Regulation of adenosine receptors has been linked to
the signal transduction mechanism. It has been previously
stated that adenosine can both stimulate and inhibit
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adenylate cyclase activity via receptors that are
pharmacologically distinct. The potency series of R-
PIA>adenosine>NECA is distinctive for the A^ (inhibitory)
receptor whereas the reverse is true for the A2
(stimulatory) receptor (Wolff et al., 1981). Rodbell
(1980) reported that GTP (G) regulatory proteins were
required by these receptors to mediate the effects of
adenosine on adenylate cyclase activity. The involvement
of the G-regulatory proteins in this process was confirmed
by the use of the cholera and pertussis toxins which
selectively modify ADP-ribosylation reactions. Cholera
toxin labels the alpha-subunit of the Gg (stimulatory)
subunit and the pertussis toxin labels and modifies the Gj^
(inhibitory) alpha-subunit. Cholera toxin enhances the
stimulatory actions of the A2 receptor (Lad et al., 1980)
which causes prolonged activation of adenylate cyclase,
whereas pertussis toxin eliminates the Gj^-mediated
activities which prevents the A^ receptor from inhibiting
adenylate cyclase (Hazeki and Ui, 1981). Thus the G
proteins are responsible for inducing the continued
stimulation of adenylate cyclase activity.
Recent evidence indicates that adenosine receptors
are linked to signal transduction mechanisms other than
the adenylate cyclase signaling system. These mechanisms
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include effects of adenosine on: (1) plasma membrane ion
channels (Changeux et al., 1984), (2) cardiac potassium
channels (Kurachi et al., 1876), and (3) calcium channels
(Peterson and Maruyana, 1984; Kameyama et al., 1985).
Ligeuids Used to Characterize Adenosine Receptors
A number of agonists and antagonists radioligands of
diverse structures (Table 2) has been developed that bind
to adenosine receptors (Research Biochemicals Incorp.,
1990). These ligands have made possible the
characterization of transport sites and receptors. Since
1980, several A^ receptor selective radioligands have been
developed but only a few selective A2 receptor agonists
have been reported. CV-1808 (2-phenylaminoadenosine), a
coronary vasodilator from Takeda, was the first A2
selective compound to be identified. CGS 21680 and its
analog PAPA-APEC are the most selective A2 high affinity
agonists reported today (Barrington et al., 1989; Stiles,
1989) and are used as specific radioligand photoaffinity
probes. Yeung and Green (1983) performed successful
studies on the A2 selective receptor using the
nonspecific ligand, [^H]-N-ethylcarbosyamido-adenosine
(NECA). Likewise, A^ selective photoaffinity ligands
^^^I-APNEA and ^^®I-AZPNEA were developed in 1985 (Stiles
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Table 2. Adenosine ^onlst and Antagonist Ligands Employed
In the Characterization of Adenosine Receptors
Aponists Selectivity
Adenosine
Adenosine amine congener (ADAC) A,
N6-Benzyladenosine At > A2
2-ChIoroadenosine A| > A2






ENBA, (S)- (PD-126280) A,
5'-N-Ethylcarboxamidoadenosine (NECA) A2 = At
N6-Methyiadenosine —
5'-N-Methylcarboxamidoadenosine A2 > At
1 -Methy lisoguanosine A,
2-Methylthio-ATP P2x
N®-Phenyladenosine A| > A2









1,3-DimeihyIxanthine (Theophylline) At > A2
1,7-DimeihyIxanthine (Paraxanthine) A| > A2
3,7-Dimethylxanthine (Theobromine) At > A2
1^-Dipropyl-7-methylxanthine A2 > A^
l,3-Dipropyl-8-p-sulfophenylxanthine At > A2
7-(/3-Hydroxyethyl)theophylline —
3-Isobuty1-1-methyIxanthine (IBMX) At > A2
PACPX At
8-Phenyltheoph’ylline At
3-(n-Propyl)-xanthine (Enprofylline) At > A2
8-(p-Sulfophenyl)-theophylline A| > A2
1,3.7-Trimethylxanthine (Caffeine) —
Xanthine amine congener (XAC) At
Other
AHPIA, R(-)- At photoafflnity
Dipyridamole Uptake inhibitor
24
et al.) to probe the receptor and demonstrated binding
that was reversible, saturable, stereospecific, and
selective to this receptor in a variety of tissues. The
receptor ligands used most Include CHA, 2-CADO, and R-
PIA, although the N-6 cyclopentyl analog of adenosine
(CPA) is approximately 6-fold more selective that CHA as
an A^ ligand (Bruns, 1984; Daly, 1984). A second group of
compounds, the xanthine-adenosine antagonists were
developed and used to label A2 sites and other
"antagonist" recognition sites in brain tissue. The best
known antagonists of adenosine receptors are theophylline,
caffeine and theobromine.
Future Trends in Adenosine Research
Since the actions of adenosine in regulating coronary
blood flow was recognized by Drury and Szent-Gyorgi in
1929, a vast accumulation of information on the effects of
adenosine in cardiovascular function has proven
enlightening, but has failed to resolve the question of
the nucleoside's role as a therapeutic agent or
physiological modulator in cardiovascular function. To
date, the goal to clearly define the nature of the
nucleoside transport sites labeled by [^H]NBMPR in the
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heart has yet to be accomplished. However, receptor
binding studies, the development of new ligands and the
isolation and cloning of the two adenosine receptor
subtypes (Stiles et al., 1985; Barrington et al., 1989)
have provided data that can be instrumental in augmenting
further investigations concerning the potential actions of
adenosine. Likewise, the relationship of adenosine
receptors to membrane G proteins, ion channels, and
second-messenger systems (Cooper and Caldwell, 1989) has
proven very valuable in investigating newer areas of
adenosine research.
An abundance of data reveal adenosine to exert potent
effects both directly and indirectly on cardiovascular
function. Direct effects occur through the activation of
and A2 receptors in the heart and by receptor
interactions in the peripheral vasculature, CNS and the
kidney while indirect effects occur via its antiamine
effects and its effects on renin production.
Nevertheless, the complexities of these responses and
their interrelationships still require further
investigation. A schematic diagram of the potential
effects of adenosine mediated responses is given in
Fig. 2.
Figure 2. Schematic Diagram of the Potential Effects of
Adenosine Mediated Responses.
The effects of adenosine on blood pressure are
complex, occurIng via both direct and indirect
mechanisms. Ado = Adenosine. Vertical arrows
















Adenosine's role as a hypotensive agent makes it an
important research area of cardiovascular function.
However, an understanding of its mechanisms of action and
its interrelationships remains unclear. It is important
that adenosine's pharmacological properties and
pathophysiological role be thoroughly and aggressively
investigated if a cohesive understanding of its




Male Heartley albino guinea pigs (400-450 g) were
purchased from Buckberg Laboratory Animals, Inc. (Thomkins
Cove, NY) and housed in the animal care facility of
Morehouse School of Medicine.
Drugs and Chemicals
Drugs and radioligand for these studies were obtained
from the following sources: [^H]NBMPR (sp. act. 0.5
mCi/mole) from Dupont, New England Nuclear Company
(Boston, MA); ferrocytochrome C, potassium ferricyanide,
cytochrome c oxidase, adenosine, NECA, CHA, GTP, 2-
Chloroadenosine, cAMP, cGMP, ATP, GDP, R-PIA, S-PIA,
dipyridamole, CPA, NBTGR, EGTA, Ouabain, cGMP and
papaverine, from Sigma Chemical Company (St. Louis, MO);
theophylline, theobromine, caffeine, CV-1808, MECA, CPCA
from Research Biochemical (Natick, MA); and Ecoslnt from
National Diagnostic Inc. (Manville, NJ). All other
materials were of the purest available grades and were
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purchased from Fisher Scientific Company (Norcross, GA)
and Electron Microscopy Science (Ft. Washington, PA).
Experimental Procedures
Isolation and Preparation of Cardiac Mitochondria
Mitochondria were isolated following a modified
procedure of Jaqua-Stewart et al. (1979) and Chance and
Hagihara (1963) as modified by Tyler and Gonze (1967).
Male Hartley albino guinea pigs (400-450 g) were
anesthetized with ethyl ether and decapitated. Hearts (5-
10 g) were quickly excised, trimmed, and rinsed 2-3 times
in 0.25 M sucrose. Ventricles were finely minced and
washed in ice-cold SMET buffer that contained 0.25 M
sucrose, 70 mM mannitol, 0.2 mM EGTA, and 5 mM Tris-HCl
(pH 7.4) until all excess blood was removed. The minced
tissue was homogenized briefly (5 sec) in 4 vol (w/v) of
SMET buffer using a Polytron, Ultra Turrax Tissue
Processor, at a rheostat setting of 4. The homogenate was
centrifuged at 25 x g for 5 min. The supernatant was
decanted and saved. The sediment was then subjected to a
series of homogenizations and slow centrifugations as
described above. All supernatants were saved and pooled,
filtered and centrifuged at 9800 x g for 10 min. The
mitochondrial pellets were washed twice by centrifugation
at 9800 X g for 10 min each. The final pellets were
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resuspended in 0.8 ml to 1 ml of SMET buffer per gram
original tissue weight and homogenized in a motor-driven
Potter-Elvehjem homogenizer to yield a uniform suspension.
This suspension was subjected to homogenization with the
Polytron, Ultra Turrax Tissue Processor, at a rheostat
setting of 1 and then diluted to a protein concentration
of 0.1-0.2 mg/ml and kept on ice for immediate use. All
isolation procedures were carried out at 0-4°C using
freshly prepared mitochondrial fractions. Protein was
assayed by the method of Lowry et al (1951). The entire
isolation procedure is schematically described in Fig. 3.
Purification of Cardiac Mitochondria
The purity of the mitochondrial fraction was
determined using enzyme markers and by electron
microscopic examination. Cytochrome c oxidase was used
as the marker enzyme to identify the fraction as being of
mitochondrial origin, while Na*-K*-ATPase activity and
Ouabain sensitive Na*-K*-ATPase activity (markers for the
sarcolemma) and Ca"^^ sensitive-Mg**-ATPase activity
(marker for the sarcoplasmic reticulum ) were used to
assess membrane cross-contamination. The enzyme
activities were compared in the total crude homogenate,
pooled supernatant, and purified mitochondrial membranes.
All assays were carried out at 0-4°C except where
Figure 3. Isolation Scheme of Mitochondria from Guinea
Pig Heart.
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Ventricular Tissue (5-10 g)
T
-Homogenate
a) rinse 2-3 times in 0.25 M
sucrose
b) mince and wash in SMET
buffer to remove all blood
c) homogenize in 4 vol SMET


















indicated. The procedures used to assess the purity of
the mitochondrial fractions are described below.
Marker Enzyme Assays
Cytochrome C Oxidase Assay
The actiyity of this enzyme was assayed by the
spectrophotometrie procedure of Wharton and Tzagoloff
(1967). This assay measures the oxidation rate of
ferrocytochrome c by following the decrease in absorbance
of its alpha-band at 550 nm. A solution containing 0.10
ml of potassium phosphate buffer (0.01 M, pH 7.0), 0.07 ml
1% ferrocytochrome C (reduced cytochrome c), and 0.83 ml
water was added to two cuyettes with a 10 mm light path.
A blank cuyette was oxidized with 0.01 ml potassium
ferricyanide. The reaction was initiated at 38°C by the
addition of 10 pi tissue suspension to two cuyettes and 10
pi cytochrome c oxidase to two different cuyettes (protein
concentration of 0.30 mg/ml). The decrease in absorbance
was measured at 550 nm eyery 15 sec. Cytochrome c
actiyity was defined in terms of the Ist-order yelocity
constant. The specific actiyity was calculated from the
known concentration of cytochrome c and cytochrome oxidase




All assays were performed in triplicate at 37°C.
ATPase activity was determined by the following procedure.
Tissue samples (100 )jig-200 pg) were incubated for 5 min in
1 ml final volume of a basic incubation medium. The medium
for Mg'^^-Na*-K^-stimulated and Ouabain sensitive ATPase
activity contained 50 mM Tris-HCl (pH 7.4), 4 mM MgCl2,
and 1 mM EGTA. Ca**-stimulated-Mg'*’* dependent APTase
incubation medium contained 2 mM CaCl2 instead of EGTA.
Total ATPase activity was measured by incubating tissue
samples in a total activity buffer containing 10 mM KCl,
100 mM NaCl, 50 mM Tris-HCl (pH 7.4), 4 mM MgCl2, ImM
EGTA, 3mM CaCl2 and 0.30 mM Ouabain. The reaction was
initiated after the 5 min incubation by the addition of 4
mM ATP and terminated after 10 min by the addition of 1 ml
of 12% (w/v) tricholoroacetic (TCA), followed by the
removal of the denatured protein via centrifugation at
2000 X g for 10 min. A 1 ml aliquot of the supernatant
was assayed for inorganic phosphate using a colorimetric
Fiske SubbaRow inorganic phosphate kit. The assay was
calibrated by constructing a standard curve of known




Mitochondrial suspensions were fixed in 2.5%
gluteraldehyde in 0.10 M cacodylate buffer, pH 7.4 for 24
h at 4°C. The fixed suspension was pelleted at 1,000 x g
for 10 min. Pellets were washed twice in cacodylate
buffer in 10% sucrose and then post-fixed in 2% osmium
tetraoxide (Og04) for 1 h. Dehydration was done in an
ethanol series at room temperature with an interchange of
propylene oxide followed by embedding in Epon 812. Thin
sections were cut with a Porter-Blum ultramicrotome using
glass knives and were doubled stained with uranyl acetate
and lead citrate. The sections were examined with a Jeol
JEM-1200 EX electron microscope.
Characterization of Mitochondrial Fractions
f^HlNBMPR Binding to Intact Mitochondria
Binding assays were carried out in a final incubation
volume of 1 ml that contained 0.50-0.55 ml Tris-HCl (pH,
7.4), 0.40 ml mitochondrial suspension in the absence or
presence of 0.05 ml of a nonspecific displacer or NBNPR
inhibitor and 0.05 ml of graded concentrations of
[^HlNBMPR. Binding was terminated after 1 h incubation
(room temperature), by rapid vacuum filtration over
Whatman GF/b filters with two 5 ml washes of ice-cold
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Tris-HCl buffer (50 mM, pH 7.4). [^H] Radioactivity
associated with the fractions was measured by liquid
scintillilation after filters were transferred into vials
containing 5 ml of scintillation fluid (Ecosint) and
counted in a Beckman LS5801 scintillation counter.
Specific (saturable) [%]NBMPR binding was determined by
subtracting nonspecific binding values (binding in the
presence of the nonspecific displacer) from total
[^HjNBMPR binding (binding in the absence of the
nonspecific displacer) values obtained from assays
performed in duplicate.
Statistical Analysis
Saturation isotherms were analyzed by the least
squares analysis of Scatchard (1949) plots and by the
nonlinear, multipurpose curve fitting computer program
LIGAND (Munson and Rodbard, 1980) to determine
dissociation constants (Kq) and maximal number of binding
sites (B^ajj) from the saturation data. Kjj is expressed in
nM and as fmol/mg protein. IC50 values, which
represent the concentration of the inhibitor/displacer
that inhibits the specific displaceable binding of
[^IHNBMPR by 50%, were calculated from semilog plots
employing 10 concentrations of the test compounds. These
values were determined by the GraphPad InPlot computer
program (GraphPad Intuitive Software for Science, San
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Diego, CA). In addition, Hill coefficients (”h) were
determined from the slopes of Hill plots of saturation
isotherms or competition data of I^H]NBMPR according to
the equation: log (B/B^g^-B) * n log [L]-log Kq where n is
the theoretical number of ligand binding sites per
receptor molecule, Kq the apparent dissociation constant,
®max maximum number of binding sites as determined by
Scatchard analysis, [L] the Molar concentration of
radioligand, and B the amount of radioligand bound at a
given concentration.
Values are represented as the mean + standard error
of the mean (SEM) and differences were assessed using the
Students's t-test (two-tailed) when applicable, where a
P<0.05 was taken to indicate a significant difference.
CHAPTER IV
EXPERIMENTAL RESULTS
Isolation and Purification of Mitochondrial Fractions
The investigation of [^H]NBMPR binding to adenosine
transport sites in mitochondria required a purified
mitochondrial preparation. Since obtaining sufficiently
pure mitochondrial fractions from heart tissue had proven
unsuccessful in the past (Chance and Hagihara, 1961;
Sordahl and Schwartz, 1967; Tyler and Gontz, 1967;
Brierley et al., 1968; Matlib et al., 1983), a protocol
was developed to obtain a fraction pure enough to be used
in the binding assays. In developing the protocol, the
isolation of mitochondria was carried out using various
buffers: Tris-HCl (pH 7.0); Tris maleate (pH 7.4);
potassium phosphate (pH 7.0); buffered sucrose (pH 7.2);
mannitol (pH 7.4) and SMET (pH 7.4). Isolations using
Tris-HCl and Tris maleate produced very small pellets with
protein concentrations significantly less than 0.1 mg/ml,
whereas buffered sucrose and mannitol buffers resulted in
a higher yield. While the yield was higher, the
mitochondrial pellet appeared broken and damaged as
indicated by the light brown to beige color and very
fluffy, soft texture. Furthermore, electron microscopic
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examination of mitochondria isolated in buffered sucrose
revealed a large number of swollen mitochondria with
ruptured or lysed outer membranes and artifactual remnants
from other subcellular organelles (shown in Fig. 4).
Additional artifacts that included blebblng and liposomal
extrusions were also evident and are also seen in Fig. 4.
These findings are consistent with the effect of sucrose
and phosphate buffers on mitochondria as reported in the
literature (Schnaitman and Greenwalt, 1986; Tzagoloff,
1982). In accord with reports in the literature, the SMET
buffer produced mitochondrial pellets that exhibited a
significant yield, higher protein concentrations, and good
appearance (Nedergaard and Cannon, 1979; Tzagoloff, 1982;
Dhalla et al., 1984).
Determination of Purity of Mitochondrial Fractions
The isolation procedure used to extract mitochondria
from guinea pig ventricles yielded a substantially pure
fraction, and electron microscopic examination of this
fraction revealed intact mitochondria with minimal
contamination by other subcellular organelles (see Figure
5). Further examination of the crude homogenate, pooled
supernatants and the mitochondrial suspension via marker
enzymes yielded additional evidence to support the finding
of minimal contamination. The data in Table 3 indicate
Figure 4. TEH Micrographs of Mitochondria Isolated from
Guinea Pig Ventricular Tissue.
The mitochondrial preparation shows artifactual
remnants and contamination by other subcellular
organelles. Some autolysis is evident (4-A).
The isolation was done in a buffered sucrose
solution (x10,200). Similar results occurred
using a potassium phosphate buffer (4-B).
Contamination has been reduced but autolysis is
still prominent. Several cells are swollen
(x10,200).
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Figure 4. TEM Micrographs of Mitochondria Isolated from
Guinea Pig Ventricular Tissue.
Evidence of swollen cells, autolysis, and
contamination by sarcoplasmic reticulum can
be seen in 4-C (x10,200).
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Figure 4. TEM Micrographs of Mitochondria Isolated from
Guinea Pig Ventricular Tissue.
Micrograph 4-D shows a fairly clean preparation
of intact mitochondria with evidence of
blebbing and mitochondria undergoing
proliferation. Autolysis and swelling have
been reduced (x4,400).
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Figure 5. TEM Micrographs of Intact Cardiac Mitochondria
Isolated from Guinea Pig Heart.
The figure shows a relatively pure fraction of





Table 3. Marker Enzyme Activities in Mitochondrial




Na'^-K*-ATPase 11.1+ 0.33 0.88+ 0.02 0.33+ 0.02
Ouabain-Sensitive-
Na'^-K*-ATPase
6.9+ 0.44 3.8 + 1.20 0.43+ 0.02
Ca'*’'*’-Stimulated-
Mg'^'^-ATPase




The enzyme activities were determined as described in
Materials and Methods. All APTase activities were
expressed as jjimoles Pi/mg protein whereas the activity of
cytochrome c oxidase was given as jjunoles cytochrome c
oxidase mg protein per min. Each value is a mean + SE of
3 experiments using separate preparations. CHM= crude
homogenate; PS = pooled supernatant; MT = mitochondria.
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that the pooled supernatant and mitochondrial fractions
contained very low Na^-K^-ATPase and Ca^^-Stimulated-Mg"^*-
ATPase activities with no appreciable differences between
them as compared to the crude homogenate. There was
however, a marked increase in Ouabain-sensitive-Na*-K‘*’-
ATPase activity in the pooled supernatant in comparison to
the mitochondrial fraction. With regard to cytochrome c
oxidase, specific activity in the mitochondrial fraction
was enriched approximately 4-fold with respect to the
corresponding enzyme activity in the crude homogenate
(0.7782 + 0.010 pmol/mg protein per min and 0.1801 + 0.003
pmol/mg protein per min, respectively). These findings
appear to confirm that the preparations employed in this
study are enriched with relatively pure intact
mitochondria (Dhalla et al., 1976; Palmer et al., 1977;
Sordahl and Stewart, 1980).
Binding Parameters for Radioligauid Equilibrium Binding
Assay
With the exception of protein concentration,
association and dissociation binding kinetics, all binding
parameters used were identical to those employed in the
established binding assay of Williams and colleages (1984)
as described in Materials and Methods. Subsequent protein
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linearity studies determined the optimal protein
concentration to range from 0.20-0.40 mg protein per ml.
Characterization of [^HjNBMPR Binding to Guinea Pig
Cardiac Mitochondria
Kinetics of r^HlNBMPR Binding to Mitochondrial Fractions
The kinetics of association and dissociation of
[^H]NBMPR binding to guinea pig cardiac mitochondria is
illustrated in Figure 6. Binding reached equilibrium with
0.20 nM [^H]NBMPR at 30 min of incubation at room
temperature and remained at equilibrium for at least 120
min (Fig. 6). However, incubation was continued for 45
min to ensure the attainment of equilibrium and optimal
binding levels. The initial rate constant (Kobs)f
calculated using the LIGAND computer program, was 0.439
min“^. The addition of 30 uM unlabeled NBMPR completely
reversed binding (Fig. 7) with a dissociation rate
constant (K.^) of 0.037 min”^ (K_^ = 0.693/half time of
dissociation). A value of 0.018 nM was calculated (Kp
= K_i/K+^, where =KQj3g-K_i). Nonspecific binding was
less than 19% in all experiments.
Analysis of the saturation data yielded nonlinear
plots and a representative Scatchard plot of the
nonlinear saturation isotherm for [^H]NBMPR binding is
shown in Figure 8. Computer analysis of the data revealed
Figure 6. Association Curve for [^HjNBMPR Binding to
Guinea Pig Cardiac Mitochondria.
Mitochondrial fractions were incubated with
0.20 nM ^H]NBMPR at room temperature,
filtered and then washed at the times
indicated. Binding equilibrium was reached
in approximately 30 min. was
determined to be 0.43min_i.
SPECIFICBOUND(Fmol/mgpr tein) oo—* oN>̂oO
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Figure 7. Dissociation Curve for [%]NBMPR Binding to
Guinea Pig Mitochondria.
Unlabeled NBMPR (30 >jiM) was added to
mitochondria that had been incubating
for 60 min with [^H]NBMPR. Binding was
completely reversed with a t^ of 18.7 min.
BOUND
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Figiire 8. Representative Scatchard Plot of Saturation
Isotherms of [^HjNBMPR Binding to Guinea Pig
Cardiac Mitochondrial Fractions.
Mitochondrial fractions were prepared and
assayed as described in Materials and Methods.
Scatchard plots were nonlinear which may
indicate the presence of 2 classes of binding
sites. Specific binding was measured as
described under Materials and Methods. All
assays were performed in duplicate, and this
figure is representative of similar
experiments conducted 4 times.
Bound/Free
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curvilinear plots which may suggest the presence of two
classes of binding sites. These curvilinear Scatchard
plots (n=4) were analyzed by the LIGAND computer program
(Fig. 8) and found to be consistent with the presence of
two classes of binding sites with dissociation constants
(Kjj) values of 0.006 nM + 0.002 and 0.029 nM + 0.012 and
receptor density values of 17 + 2 fmol/mg protein
and 177 + 27 fmol/mg protein for the high and low affinity
sites, respectively. The Hill coefficient values
estimated from Hill plot analysis of this data ranged from
0.99-1.04, suggesting no cooperativity between binding
sites ( Figure 9). This observation may be indicative of
sites that interconvert between high and low affinity
states for the ligand (Klotz et al., 1989; Williams et
al., 1990).
Because binding appeared biphasic with intact
mitochondrial fractions, studies using the crude
homogenate and pooled supernatants were done to determine
if binding was similar. All Scatchards studied appeared
biphasic and the data plus Hill coefficients are found in
Table 4. The highest density of binding sites was located
in the homogenate fraction and the lowest in the
mitochondrial fraction.
Additional experiments were performed in an attempt
to clear up specific concerns and discrespancies about the
Figure 9. Hill Plot of [^H]NBMPR Binding on Cardiac
Mitochondria.
Hill plot analysis of the saturation data
resulted in Hill coefficients of the Hill
slopes ranging from 0.99-1.04. The plot
is representative of 4 experiments that
yielded similar results. Hill
coefficients for the saturation data are





Table 4. [^H]NBMPR Binding Parameters in Fractions of































Fractions were prepared as described in Materials and
Methods. Binding parameters were determined by Scatchard
analysis using LIGAND computer program. The experiment
was repeated 4 times with similar results. The data
presented are means + S.E. of the means. *^11= Hill
coefficient. HM = Homogenate; PS = Pooled Supernatant;
MT = Mitochondria. There was no statistical difference
between the fraction (P>0.05).
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use of SMET buffer in the radioligand binding assays. The
radioligand binding assays were repeated under varied
conditions. One experiment involved binding of [^H]NBMPR
on mitochondrial pellets that had been washed in SMET and
then suspended in Tris-HCl. The homogenization procedure
was not altered. Another variation involved performing
binding experiments on intact mitochondria that had been
washed and suspended in Tris-HCl and homogenized as in the
original preparations. A third experiment was done
exactly as above except that the pellet was homogenized at
an increased speed with the Polytron homogenizer. The
gentle disruption with the Potter-Elve jhem homogenizer was
omitted in order to produce broken mitochondrial
membranes. Scatchard analyses of the data revealed linear
Scatchard plots in all preparations studied.
Concurrently, a similar and significant increase in
binding site densities was observed in all preparations
(Bjiaxes fmol/mg protein, 793 fmol/mg protein, and
731 fmol/mg protein in experiments 1, 2, and 3,
respectively) as compared to the nonlinear Scatchards of
the original preparations fmol/mg protein). The
results of these experiments are shown in Figure 10.
Selectivity of f^HlNBMPR Binding Sites
Displacement and pharmacology studies for various
adenosine analogs, xanthine antagonists and nucleotides
Figure 10. Scatchard Analysis of [^H]NBMPR Binding to
Broken and Intact Mitochondria using Tris-HCl
Buffer.
Increasing concentrations of [^HjNBMPR were
incubated with broken and intact mitochondria
prepared as described in the text. Data
points represent the results from single




tested are illustrated in Table 5 and the IC5Q values are
listed in Figure 11. The adenosine transport inhibitors
were the most potent inhibitors of [^HJNBMPR binding.
NBMPR and NBTGR were equipotent (IC5q=0.001 ]jlM) and were
44 times more potent than dipyridamole (1^50=0.044 ]jlM) .
Adenosine (IC5q=1.29 pM) was approximately twice as
potent than the most potent receptor ligand CPA
(IC5q=2.28 pM) which was 11 times more potent than CHA,
the agonist next in potency (IC5q=25 )jiM)in inhibiting
binding. In addition, S-PIA was twice as potent as its
stereoisomer R-PIA which is not in agreement with a
previous report on the selectivity of these two compounds
(Stone, 1985). The agonist rank order of potency for the
A^-receptor ligands was: CPA>CHA>S-PIA>R-PIA. In
comparison, MECA was the most potent A2 receptor ligand
(1050=1.74 pM). The agonist rank order of potency for the
A2-receptor ligands was: MECA>CV-1808>2CADO>CPCA. While
the adenosine receptor ligands were approximately 5 orders
of magnitude less potent in inhibiting binding, a fairly
extensive list of purines, nucleotides and methylxanthines
were poor Inhibitors of NBMPR binding at the
concentrations tested (see legend in Table 5). IC50
values for NECA, papaverine, caffeine and theobromine
could not be calculated because their inhibition profiles
were not clearly dose responsive.
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N®-Cyclopentyladenosine (CPA) 2.28 + 0.09 0.645
N®-Cyclohexyladenosine (CHA) 25 + 0.05 1.020






2-Phenylaminoadenosine 1 .87 + 0.18 1.180
(CV-1808)
2-Chloroadenosine (2-CADO) 24 + 1.90 0.612
5'-N-Methylcarboxyamidoadenosine
(MECA)










Nitrobenzylthioinosine (NBMPR) .001 + 0.0002 1.250
Nitrobenzylthioguanosine (NBTGR) .001 + 0.0008 0.974
Dipyridamole (DPR) .044 + 0.0030 2.280
Nucleosides
Adenosine 1.29 + 0.057 0.801
The IC50 value for each inhibitor was determined by
testing 10 concentrations for inhibition of [^H]NBMPR
binding (0.20 nM). Each compound was tested at least
twice in duplicate and the values were averaged. GraphPAD
InPlot computer program was used to calculate IC50 values
and Hill cofficients (^H). A number of compounds were
tested that showed no appreciable effect on binding at up
to 1 mM. These included: nucleotides - ADP, AMP, GMP,
GDP, ATP, CAMP, and cGMP. Inhibition of NECA,
Theobromine, and Caffeine did not appear to be dose
responsive, nc = not calculated.
Figure 11. Displacement Curves of [^H]NBNPR Binding by
Nucleoside Tremsport Inhibitors and Adenosine
Analogs.
IC50 values for various adenosine agonists and
antagonists, nucleoside transport Inhibitors,
and nucleotides were determined using 0.20 nM
[^H]NBMPR and 10 concentrations of the test
compounds. These results represent 3
experiments with similar results. IC5Q values
were calculated using GraphPad InPlot computer
program. Shallow curves are generally
indicative of Hill coefficients <1 which





Nucleoside transport is a facilitated diffusion
system which can transport a variety of nucleosides.
Several studies have been done in an attempt to fully
characterize this somewhat simple carrier-mediated
transport system in order to better understand the role of
nucleoside transport and adenosine in cardiovascular
function. However, problems have persisted in the past
(i.e., the high turnover rate of the nucleoside
transporter, and the limited existence of radiolabeled
inhibitors of nucleoside transport that can be used to
characterize nucleoside transport systems and the rapid
uptake of nucleosides) that contributed to the difficulty
in measuring transport. Thus, it is not surprising that
the available data regarding nucleoside transport in
different systems have been subject to different
interpretations that resulted in uncertainties about the
role of nucleoside transport systems.
Nucleoside transporter function employing radioligand
probes and radioligand binding have been investigated in
a variety of crude membranes, intact cells, and cellular
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fractions. Although the studies have been informative,
there is still much to learn about nucleoside transport
and its role in different physiological systems.
To further investigate the role of adenosine and
nucleoside transport in cardiovascular function, the
characterization of adenosine transport sites in guinea
pig cardiac mitochondria using [^HJNBMPR as a radioligand
probe was studied. Interestingly, this is the first
attempt (to this investigator's knowledge) to examine
nucleoside transport in mitochondria even though the
organelle may probably participate in more metabolic
functions than any other cellular organelle. As
previously stated, a requirement for binding studies at
the subcellular level is a relatively pure subcellular
fraction. The fulfillment of this requirement has been
difficult to accomplish in the past. The tough
collagenous fibers that make up cardiac tissue made tissue
disruption difficult to accomplish without decreasing the
amount of tissue yield and recovery of mitochondrial
protein. Thus a major effort and considerable time were
spent on developing a protocol that would yield a
substantially pure mitochondrial preparation.
Various methods described for the isolation of heart
mitochondria from the rat (Cleland and Slater,
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1953; Montgomery and Webb, 1956), rabbit (Harman and
Feigelson, 1952; pigeon (Chance and Hagihara, 1961) and
dog (Jaqua-Stewart et al., 1978) were studied. The
methods of Chance and Hagihara employed brief proteinase
(B. subtilis) digestion of tissue slices followed by
mechanical homogenization. This technique produced
reasonably good yields of functional mitochondria devoid
of other contaminating organelles and became the method of
choice for the preparation of heart mitochondria from
laboratory animals. Tyler and Gonze (1967) followed the
lead of Chance and Hagihara and employed proteinase
(Nagarse enzyme) in their preparatory procedure. The use
of proteinase subsequently became controversial when it
became evident that Nagarse was not highly selective in
its degradative actions and yielded mitochondria that
displayed protease damage. Another problem that developed
with the use of Nagarse involved the prolonged incubation
periods of the tissue (excess of 5 min) and the necessity
of relatively high concentrations of the enzyme, which
often resulted in mitochondrial damage. Additionally,
temperature had to be strictly regulated in order to
maintain the functional capabilities and integrity of the
mitochondria. As a result, alternate methods were then
designed that discontinued the used of Nagarse (Matlib et
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al., 1978). However, a satisfactory isolation procedure
was still unavailable.
Isolation procedures were proposed to significantly
enhance or decrease tissue yield and tap different
population of mitochondria from tissue (Palmer et al.,
1977; Shimada et al., 1984). Subsequently, different
populations of mitochondria were reported in ventricular
myocardium of rats and Japanese monkeys. In this regard.
Palmer and colleages combined isolation techniques and
isolated two populations of mitochondria, one clustered
beneath the sarcolemma (subsarcolemmal) and another
located between the myofibrils (interfibrillar).
Subsarcolemmal mitochondria were isolated via treatment of
heart muscle mitochondria with a Polytron homogenizer,
while interfibrillar mitochondria were released by Nagarse
digestion of the remaining tissue. Each type of
mitochondria differed not only in their location but in
their biochemical properties as well. Monkey myocardium
was reported to contain a third population of mitochondria
located around one pole of the nucleus (perinuclear) in
addition to the subsarcolemmal and interfibrillar
mitochondria (Shimada, 1984).
Since the main obstacle in isolating pure heart
mitochondria was the fibrous make up of cardiac tissue.
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methods of other investigators (Chance and Hagihara, 1961
as modified by Tyler and Gonze# 1967; Chance and Hagihara,
1961; Eastabrook and Pulman, 1967; Jacqua-Stewart et al.,
1978; Mela and Seitz, 1979; Sordahl and Stewart, 1980)
were attempted without success by this author. A
consistent problem encountered was in the method of tissue
disruption and choice of buffers. In earlier isolation
procedures, Nagarse digestion of the tissue in all buffers
used resulted in extremely small pellets that appeared to
have layers of damaged mitochondria or some other material
suspended on top of each other. Several buffers (Tris
maleate, buffered sucrose, dilute potassium phosphate,
Tris-HCl, KEA (KCl, EGTA and BSA), and SMET were employed
in the isolation procedures. With the exception of the
SMET buffer, pellets were produced that were low in
mitochondrial protein concentrations, of poor quality in
color, size, and texture, and that often adhered to the
sides of the centrifugation tube. The tubes had to be
shaken in order to loosen the pellets, which resulted in
their breakage. Another problem involved tissue
disruption. Homogenization problems occurred when the
tissue was disrupted in the absence or presence of
Nagarse. These problems included incorrect speed of
homogenization that prevented the production of
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an even homogenate without mitochondrial damage; excessive
polytron homogenization; improper dilution of tissue
before and after homogenization with the Potter-Elvejhem
homogenizer; and undue delay in carrying out the entire
isolation procedure. A final problem to be resolved was
that of centrifugation speed. Earlier centrifugations
were too fast, which caused the mitochondria to sediment
out with lipids and other contaminants. Some of the
mitochondria may have also sedimented out in nuclear
fractions which were discarded and could explain the low
tissue yield, in some instances.
After numerous attempts and many trials and errors,
a protocol (Fig. 3) was developed that was a modification
of the procedures of Jaqua-Stewart et al. (1978) and
Chance and Hagihara (1963) as modified by Tyler and Gonze
(1967), which yielded a mitochondrial fraction from guinea
pig heart tissue that was about 4-5 times purer than the
crude homogenate as verified by enzyme marker assays
(Table 3). This finding is similar to those suggested by
other investigators (Fleischer et al., 1978; Dhalla,
1983). Moreover, electron microscopic examination
revealed a heterogeneous fraction that appeared to consist
of perinuclear mitochondria and some subsarcolemmal
mitochondria. These mitochondrial populations were
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identified based on the morphological description reported
by Shimada and colleages (1984).
Surprisingly, a novel finding of this study was the
demonstration of [^H]NBMPR binding in mitochondrial
fractions, even though Scatchard analysis of the
saturation data were nonlinear, suggesting two classes of
binding sites. These nonlinear or curvilinear Scatchard
plots may have been induced by SMET buffer as a result of
the sucrose and/or mannitol interfering with binding,
thereby, lowering the binding site density. However, it
is difficult to accept this hypothesis without further
investigations because it is logical to postulate, from a
structural-activity perspective, that the NBMPR is binding
to some other site rather than to nucleoside transport
sites. An alternative suggestion is that NBMPR may only
be able to bind to a small number of transporter sites in
intact mitochondria or that the organelle may only possess
a very small number of binding sites at the onset.
Disrupting the mitochondria, allows the probes access to
internal binding sites that override the surface binding.
Another avenue to consider is the incubation procedure in
the assay. Since the incubation of the mitochondria was
carried out at room temperature, allowing for subsequent
internalization of the probe, the rapid uptake of the
probe would then allow it to label internal high and low
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affinity sites. Furthermore, performing the assay at room
temperature with intact mitochondria could also lead to
further metabolism of the radioligand which was analyzed
in addition to transport.
The additional experiments using Tris-HCl buffer
instead of SMET yielded expected results. When intact
mitochondria were exposed to Tris, their ability to remain
intact was eliminated. Tris, which is hypotonic to
mitochondria, induced swelling and lysis of the intact
organelles. Once this occurred, NBMPR was able to bind to
a conglomerate of heterogenous material and membranes
which resulted in the production of linear Scatchard plots
with increased binding sites. However, the actual binding
constituents were not determined.
To further explore the possibility that sucrose,
mannitol, or SMET buffer interfered with binding, an
additional experiment was performed using broken
membranes. The data revealed that binding was decreased
(up to 75% ) when sucrose, mannitol, or SMET was added to
the assay instead of Tris-HCl. A reasonable explanation
to consider is that the mitochondria had not been
subjected to a Polytron rheostat setting high enough or
long enough to ensure that the membranes were completely
broken. Consequently, the addition of SMET, sucrose, or
mannitol to these broken mitochondria caused the membranes
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to reseal, thereby causing a decrease in binding when
compared to Tris.
Experiments characterizing the binding of [^HjNBMPR
to guinea pig heart mitochondria demonstrated that binding
was saturable with time and reversible. The dissociation
curve was nonlinear with a tyf2 of 18.7 min indicating the
possible existence of more than one dissociation site.
Similarly, the nonlinear Scatchard plots of the binding
isotherm data suggest the possibility of two classes of
binding sites with high and low affinity for the ligand.
A Kjj value of 0.018 nM was calculated from the association
and dissociation rate constants which is in close
approximation of the Kq value of 0.029 nM of the low
affinity site determined by Scatchard analysis of the
saturation data. This observation may be due to the
presence of a higher number of binding sites in the lower
affinity state that constituted a large proportion of the
total binding activity. Thus, the binding kinetics of
these low affinity states were more accurately determined
under these conditions.
Hill coefficient values (”H between 0.99-1.04)
suggest, however, that no cooperativity occurs between the
binding sites which is generally indicative of a
homogenous population of binding sites. One possible
explanation for the discrepancies in the data, may be the
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possible existence of binding sites that convert between
high-affinity and low-affinity states. Additionally,
these interconvertible states of binding sites have been
reported in spare receptors of isolated rat fat cells
using the agonist photoaffinity ligand R-APHIA (Lohse et
al., 1986), in human umbilical vein endothelieum using
[^INBMPR (Williams et al., 1990) and are also
characteristic of agonist binding to beta-adrenergic
receptors (Maguire et al., 1975; Lefkowitz et al., 1976;
Kent et al., 1980).
Alternatively, the presence of two classes of binding
sites may represent ligand binding to two different
recognition binding sites on a single substrate
macromolecule, or to closely related allosteric sites in
cardiac mitochondrial preparations or possibly to more
than one type of nucleoside transporter located in the
preparations used. Moreover, the isolation procedure may
also have produced some mitochondrial artifact that was
sensitive to the radioligand probe which may support the
hypothesis that different populations of mitochondria
released from cardiac tissue based on the homogenization
procedure, possess morphological and functional
differences (Palmer et al., 1977). It is then
conceivable, that binding might be somehow linked to the
morphology of the mitochondrial population.
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The degree of interaction of various adenosine
receptor agonists and antagonists, adenosine transport
inhibitors and nucleotides with [^H]NBMPR was also
examined. The rank order of potency of the adenosine
receptor agonists (CPA>CHA>S-PIA>R-PIA= Ai receptor and
MECA>CV-1808>2CADO>CPCA= A2 receptor) for the [^H]NBMPR
binding, fits neither the A^ receptor profile
(CPCA>CPA>CHA>R-PIA>2-CADO>NECA>S-PIA>CV-1808) or the A2
receptor profile (NECA>MECA>2-CAD0>CV-1808=R-
PIA>CPA=CHA>S-PIA) (Varney and Skidmore, 1985; Burnstock
and Kennedy, 1985; Bruns et al., 1987; GilfIlian et al.,
1989; Trivedi et al., 1990). The interaction of [^H]NBMPR
with the A^ receptor is also unlikely since S-PIA appeared
to be twice more potent than its stereoisomer R-PIA, in
displacing the radioligand which may indicate little, if
any, stereoselectivity. R-PIA had been shown to be
approximately 30-200 times more potent than S-PIA at the
A-i receptor in the brain and spinal cord membrane
preparations (Daly, 1982; Geiger et al., 1984).
Furthermore, the adenosine receptor antagonists and the
nucleotides were all virtually ineffective on [^HlNBMPR
binding at concentrations up to 1 mM. This observation is
interesting because ATP, ADP, 5'-AMP and theophylline have
been shown to be inactive at the intracellular P site in
brain and spinal cord (Daly, 1982). In comparison, all
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IC50 values of the compounds studied, with the exception
of the adenosine transport inhibitors (NBMPR, NBTGR, and
Dipyridamole), adenosine, and the receptor ligands CV-1808
(A2) and CPA (A^), indicated low affinity of these
compounds for the ligand. Interestingly, like the potent
nucleoside transport inhibitors NBMPR and NBTGR, CHA and
CV-1808 displayed Hill coefficients of 1 indicating that
no cooperativity occurred between the sites. Taken
together with the observations of Hill coefficients less
than one in almost all the compounds, these findings can
be interpreted on the basis of structure-activity
relationships, tissue uptake and subsequent intracellular
metabolism (Davies, 1982). The potent inhibitory actions
of NBMPR and related compounds have been attributed to the
6-N-substituted nitrobenzyl and 9 ribosyl moities
extending from the purine ring (Paterson and Oliver,
(1971). Unlike the adenosine receptors, the P site cannot
accept alterations in its purine ring. CHA and the
stereoisomers R-PIA and S-PIA are similar to NBMPR in that
they all possess the 9 ribosyl group as well as the
hydrophobic ring structure at the N^ position.
Consequently, 2-CADO was less potent in displacing
[^HjNBMPR, possibly because it lacks the N® group.
Thereby, when considering the biological actions of these
receptor agonists, the inhibition of endogenous adenosine
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uptake should be considered as a contributing factor to
these effects.
Finally, a comparison study of [^H]NBMPR binding
parameters in guinea pig cardiac mitochondria and in crude
guinea pig ventricular membranes was performed. Unlike
cardiac mitochondria, [^HJNBMPR bound to a high number of
a single class of sites with high affinity (Kq =0.41 +0.08
nM and =1802 +122 fmol/mg protein). Binding was
rapid, reversible and saturable. The binding parameters
of the crude ventricular membranes are in good agreement
with values obtained from earlier studies in guinea pig
cardiac membranes (Williams and Clanachan, 1983); guinea
pig cortical synaptosomes (Hammond and Clanachan, 1982)
and in human erythrocytes (Hammond et al., 1981).
A major finding of this investigation is that
nucleoside transport sites can be labeled with [^HJNBMPR
in guinea pig cardiac mitochondrial membranes. This
observation is a step towards augmenting our knowledge
about the precise localization of cardiac nucleoside
transporters as well as establishing a possible
subcellular basis for the nucleoside transport mechanism
in myocardial function. In accordance, further studies
must be done and extended to the sarcolemma and
sarcoplasmic reticulum in order to carry out a
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comprehensive investigation of nucleoside transport at the
subcellular level in cardiac tissue.
Interpretation of the [^HjNBMPR binding data in guinea
pig cardiac mitochondria is difficult since there have
been no previous binding studies done and no physiologic
evidence is available to indicate the presence of an
adenosine transport site in this fraction. It does appear
however, that some binding may be intracellular.
It is evident from the data generated and the
questions raised as a result of this investigation, that
the molecular and subcellular basis for adenosine's role
in cardiovascular function and in nucleoside transport in
the heart is still unanswered and that further study is
warranted. However, the data generated suggest that the
mitochondria may be employed as a potential model in which
to study nucleoside transport in the heart even though the




In summary, this investigation involved the
subcellular characterization of nucleoside transport
binding sites in guinea pig cardiac mitochondria. The
data yielded some interesting results and the following
conclusions can be stated:
1) A specific transport process exists for nucleoside
(e. g., adenosine) uptake by cardiac tissue via
facilitated diffusion and is characterized by
Michaelis-Menten enzyme kinetics.
2) The results indicate that intact mitochondrial
fractions contain NBMPR binding activity mainly
of low affinity.
3) The nucleoside transport inhibitor [^H]NBMPR, binds
specifically, saturably, and reversibly, to a
transporter site that may be capable of
interconverting between high and low affinity
states that are selective for adenosine.
4) The displacement studies suggest that the sites
labeled by [^H] NBMPR do not correspond to any
known adenosine receptor (i. e., A^ or A2) or to
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the P site based on their pharmacological profiles
and order of potencies.
5) Finally, the data demonstrate that [%]NBMPR binding
occurs in guinea pig cardiac mitochondria even though
the transport mechanism is unknown. However, it has
been suggested that sufficiently high intracellular
levels of adenosine may cause it to flow down its
concentration gradient and pass out of cells through
a nucleoside transport system (Belloni et al., 1985;
Bukoski et al., 1986).
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